Biomarkers for the prediction of esophageal cancer neoadjuvant chemoradiotherapy response: A systemic review
- 8 September 2021
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 167, 103466
- https://doi.org/10.1016/j.critrevonc.2021.103466
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- Soluble interleukin‐6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapyCancer Science, 2013
- Correlation of p53 Status with the Response to Chemotherapy-Based Treatment in Esophageal Cancer: A Meta-AnalysisAnnals of Surgical Oncology, 2013
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic PerspectivesClinical Cancer Research, 2011
- Role of COX-2 in Tumorospheres Derived from a Breast Cancer Cell LineJournal of Surgical Research, 2011
- Immunity, Inflammation, and CancerCell, 2010
- Japanese Classification of Esophageal Cancer, tenth edition: part IEsophagus, 2009
- Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapyBritish Journal of Cancer, 2008
- Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagusJournal of Gastroenterology and Hepatology, 2007
- The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagusBritish Journal of Cancer, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007